FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding
Category Archives: Drug Recalls & Safety Notices
Statement from FDA Commissioner Scott Gottlieb, M.D., on the public health benefits from enactment of menu labeling
Statement from FDA Commissioner Scott Gottlieb, M.D., on the public health benefits from enactment of menu labeling
FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer
FDA approves Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer
FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies
FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies
Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Committee on Appropriations on FDA’s Fiscal Year 2019 budget
FDA Commissioner Scott Gottlieb, M.D. remarks to a U.S. Senate Subcommittee on Appropriations on the FDA’s Fiscal Year 2019 budget
Statement from FDA Commissioner Scott Gottlieb, M.D., on new enforcement actions and a Youth Tobacco Prevention Plan to stop youth use of, and access to, JUUL and other e-cigarettes
FDA announces several new enforcement actions and a Youth Tobacco Prevention Plan to stop youth use of, and access to, JUUL and other e-cigarettes.
FDA authorizes new use of test, first to identify the emerging pathogen Candida auris
FDA authorized the first test to identify the emerging pathogen Candida auris, which can cause serious infections in hospitalized patients.
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to encourage more widespread innovation and development of new treatments for opioid use disorder
FDA announces new steps to encourage more widespread innovation and development of new treatments for opioid use disorder
FDA takes new steps to advance the development of innovative products for treating opioid use disorder
FDA announces new steps to encourage and support the development of treatment options for people with opioid use disorder
Federal judge enters consent decree against Cantrell Drug Company
Cantrell Drug Company prohibited from manufacturing and distributing sterile drug products in violation of the law